Cost-effectiveness analysis of dapagliflozin for people with chronic kidney disease in Malaysia.

Published in: PloS one (2024)

The use of dapagliflozin was projected to improved life expectancy and quality of life among people with CKD, with a saving RM8,894 (USD2,148) for every quality-adjusted life-year gained and RM7,898 (USD1,908) saving for every life year gained.

Keyphrases

chronic kidney disease
end stage renal disease
climate change
peritoneal dialysis